## AMPX: Amprius Technologies, Inc. - XLI: Industrials

### Executive Summary

No thesis match: MRS_20 -16.1% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-9.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($7.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Amprius Technologies (AMPX) shifts CEO role to Tom Stepien as Kang Sun becomes advisor**
- Source: Stock Titan | 20251222T140930 | Neutral | Relevance: 100%
- Amprius Technologies announced a leadership transition where CEO Dr. Kang Sun will step down effective December 31, 2025, to become an Executive Advisor, while remaining on the board. Tom Stepien, the current President, will assume the CEO role starting January 1, 2026. The company stated that Dr. Sun's departure is not due to any disagreements regarding operations or policies.

**2. Amprius Technologies Announces CEO Transition**
- Source: Business Wire | 20251222T130930 | Somewhat-Bullish | Relevance: 100%
- Amprius Technologies has announced that its President, Tom Stepien, will become the new CEO effective January 1, 2026. Current CEO Dr. Kang Sun will retire at the end of 2025 but will remain on the Board of Directors and serve as an Executive Advisor. Stepien, who joined Amprius in May 2025, brings extensive leadership experience in technology and energy storage to lead the company's next phase of growth.

**3. Amprius Technologies announces CEO transition and executive compensation changes**
- Source: Investing.com | 20251222T150930 | Somewhat-Bullish | Relevance: 100%
- Amprius Technologies (NYSE:AMPX) announced that CEO Dr. Kang Sun will transition to Executive Advisor and remain on the board, effective December 31, 2025. Tom Stepien, current President, will succeed him as CEO starting January 1, 2026. The company detailed executive compensation for both Dr. Sun and Mr. Stepien, including salaries, bonus eligibility, and equity awards.

**4. CA-AMPRIUS-TECHNOLOGIES**
- Source: The Facts | 20251222T130930 | Bullish | Relevance: 100%
- Amprius President Tom Stepien has been appointed chief executive officer by the Board of Directors, with the change effective January 1, 2026. This announcement was made via Business Wire.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.03M) |
| Sells | 3 ($3.03M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 25.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Blackrock Inc.: 5.7% (+41.5%)
- Vanguard Group Inc: 5.0% (+37.0%)
- Driehaus Capital Man: 2.4% (+100.0%)
- Morgan Stanley: 2.1% (+41.9%)
- Citadel Advisors Llc: 1.9% (+796.4%)

### Key Risks

1. High beta (2.96) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_20 falling (-9.6% 5d) with bearish MACD, trend may be turning.
3. Insider selling cluster: $3.0M in recent transactions.
4. Elevated short interest (10.9%): bears positioning against stock.
5. Near-term weakness: 22.2% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.7x). Revenue growth strong at 71% YoY. Insider selling cluster ($3.0M in 90 days), potential headwind. Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.2B |
| Beta | 2.96 |
| 52W Range | $1.70 - $16.03 |
| Short Interest | 10.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -6.5% to -16.1% (-9.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 20.1pp (needs >4.0% for momentum thesis). AM_20 at -15.6% indicates price below own 20MA trend. Underperforming sector by 17.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.29x) but short-term weakness (below SMA20). Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -16.05% (CS: 0) | Weak |
| RSI_14 | 37.9 | Neutral |
| MACD Histogram | -0.22 | Bearish |
| vs SMA20 | 0.844x | Below |
| vs SMA50 | 0.778x | Below |
| vs SMA200 | 1.294x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $9.05
- **Stop Loss:** $7.15 (21.0% risk)
- **Target:** $10.95 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 473
- **Position Value:** $4,280.65
- **Portfolio %:** 4.28%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-03-19 (Est: $-0.04)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.06 | $-0.03 | +47.8% |
| 2025Q2 | $-0.08 | $-0.05 | +37.5% |
| 2025Q1 | $-0.09 | $-0.08 | +11.1% |
| 2024Q4 | $-0.10 | $-0.09 | +16.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*